✦ LIBER ✦

Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions

✍ Scribed by Cho, Bo-Hyun; Stoecker, Charles; Link-Gelles, Ruth; Moore, Matthew R.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Use of 13-Valent Pneumococcal Conjugate

📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 499 KB

CE1 The Cost-Effectiveness Analysis of 1

✍ Wu, D.B.C.; Chang, C.J.; Chien, L.; Fang, H.C.H.; Roberts, C.S. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB

PIN33 Pharmacoeconomic Evaluation of 13-

✍ Chuck, A.; Waye, A; Zanotti, G.; Jacobs, P.; Kellner, J.; Tyrrell, G. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Sequential administration of 13-valent p

✍ Greenberg, Richard N.; Gurtman, Alejandra; Frenck, Robert W.; Strout, Cynthia; J 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 966 KB

Erratum to Pneumococcal Polysaccharide C

✍ M. Sanford 📂 Article 📅 2012 🏛 Springer International Publishing AG 🌐 English ⚖ 57 KB

PIN43 COST-EFFECTIVENESS OF 13-VALENT AN

✍ Whillans, F; Kwan, H; Strutton, DR; Earnshaw, SR; Farkouh, R 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB